幽门螺杆菌感染第三线及后续经验性补救治疗:欧洲幽门螺杆菌管理注册研究2144例患者8年经验
该研究为国际前瞻性非干预性注册研究,评估欧洲幽门螺杆菌第三线及后续经验性补救治疗的使用、有效性和安全性,共纳入2144例治疗。多数方案根除率低于90%,优化治疗根除率高于非优化治疗(78% vs 67%,p<0.0001),仅含铋剂-甲硝唑-四环素的四联疗法和含阿莫西林-左氧氟沙星的三联疗法在部分情况下达到可接受疗效。
要点
- 优化治疗的根除率高于非优化治疗(78% vs 67%,p<0.0001)。
- 含铋剂-甲硝唑-四环素的四联疗法仅在第三线治疗时达到理想根除率。
- 2017至2021年仅44%的非10天单胶囊方案治疗使用高剂量PPI且疗程≥14天。
核心结论
- 欧洲多数地区第三线及后续经验性补救治疗的有效性欠佳。
- 仅含铋剂-甲硝唑-四环素的四联疗法(10天单胶囊或14天传统方案)和含阿莫西林-左氧氟沙星的三联疗法在部分情况下达到可接受结局。
- 临床实践指南更新5年后,经验性治疗优化原则的依从性仍然较差。
研究设计与样本
- 国际、前瞻性、非干预性注册研究,收集欧洲消化科医生的临床实践数据。
- 数据截至2021年10月在西班牙消化病学会-研究电子数据采集系统收集并质控。
- 共纳入2144例治疗,其中第三、四、五、六线分别为1519、439、145和41例。
- 所有具有三次或以上经验性根除尝试的病例均按改良意向性治疗和符合方案分析评估有效性。
主要发现
- 共使用60种不同疗法,最常处方的15种涵盖超过90%的病例。
- 所有疗法的总体有效性均低于90%。
- 优化治疗的根除率高于非优化治疗(78% vs 67%,p<0.0001)。
- 含甲硝唑、四环素和铋剂的四联疗法仅在作为第三线治疗时达到理想根除率,分别为10天单胶囊方案87%和14天传统方案(使用盐酸四环素)95%。
- 含阿莫西林-左氧氟沙星的三联疗法仅在东欧或优化时达到90%有效性。
关键数值与推荐
- 优化治疗根除率78% vs 非优化治疗67%(p<0.0001)。
- 含铋剂-甲硝唑-四环素四联疗法第三线10天单胶囊方案根除率87%。
- 含铋剂-甲硝唑-四环素四联疗法第三线14天传统方案(盐酸四环素)根除率95%。
- 含阿莫西林-左氧氟沙星三联疗法在东欧或优化时有效性90%。
- 2017至2021年,仅44%的非10天单胶囊方案治疗使用高剂量质子泵抑制剂且疗程≥14天。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the use, effectiveness and safety of Helicobacter pylori empirical rescue therapy in third and subsequent treatment lines in Europe. DESIGN: International, prospective, non-interventional registry of the clinical practice of European gastroenterologists. Data were collected and quality reviewed until October 2021 at Asociación Española de Gastroenterología-Research Electronic Data Capture. All cases with three or more empirical eradication attempts were assessed for effectiveness by modified intention-to-treat and per-protocol analysis. RESULTS: Overall, 2144 treatments were included: 1519, 439, 145 and 41 cases from third, fourth, fifth and sixth treatment lines, respectively. Sixty different therapies were used; the 15 most frequently prescribed encompassed >90% of cases. Overall effectiveness remained <90% in all therapies. Optimised treatments achieved a higher eradication rate than non-optimised (78% vs 67%, p<0.0001). From 2017 to 2021, only 44% of treatments other than 10-day single-capsule therapy used high proton-pump inhibitor doses and lasted ≥14 days. Quadruple therapy containing metronidazole, tetracycline and bismuth achieved optimal eradication rates only when prescribed as third-line treatment, either as 10-day single-capsule therapy (87%) or as 14-day traditional therapy with tetracycline hydrochloride (95%). Triple amoxicillin-levofloxacin therapy achieved 90% effectiveness in Eastern Europe only or when optimised. The overall incidence of adverse events was 31%. CONCLUSION: Empirical rescue treatment in third and subsequent lines achieved suboptimal effectiveness in most European regions. Only quadruple bismuth-metronidazole-tetracycline (10-day single-capsule or 14-day traditional scheme) and triple amoxicillin-levofloxacin therapies reached acceptable outcomes in some settings. Compliance with empirical therapy optimisation principles is still poor 5 years after clinical practice guidelines update. TRIAL REGISTRATION NUMBER: NCT02328131.
引用
- Burgos-Santamaría D, Nyssen OP, Gasbarrini A, et al. Empirical rescue treatment of Helicobacter pylori infection in third and subsequent lines: 8-year experience in 2144 patients from the European Registry on H. pylori management (Hp-EuReg). Gut. 2023. PMID: 36591610. doi:10.1136/gutjnl-2022-328232
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。